You are here
Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
CANTON, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will be hosting investor meetings at the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel in Boston, Massachusetts.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.